Published in Nucleic Acids Res on July 15, 2002
Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet (2010) 10.71
Derivation of novel human ground state naive pluripotent stem cells. Nature (2013) 5.90
FMR1: a gene with three faces. Biochim Biophys Acta (2009) 1.77
Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res (2006) 1.47
Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum Mol Genet (2010) 1.31
Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res (2008) 1.23
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet (2008) 1.16
An origin of DNA replication in the promoter region of the human fragile X mental retardation (FMR1) gene. Mol Cell Biol (2006) 1.16
The cationic porphyrin TMPyP4 destabilizes the tetraplex form of the fragile X syndrome expanded sequence d(CGG)n. Nucleic Acids Res (2003) 1.09
A distinct DNA-methylation boundary in the 5'- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet (2009) 1.05
The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome. Hum Mol Genet (2010) 1.04
FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles. J Mol Diagn (2011) 0.94
In vivo haematopoietic activity is induced in neurosphere cells by chromatin-modifying agents. EMBO J (2005) 0.92
Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Exp Neurol (2015) 0.91
Epigenetic changes and non-coding expanded repeats. Neurobiol Dis (2010) 0.91
The gene encoding the fragile X RNA-binding protein is controlled by nuclear respiratory factor 2 and the CREB family of transcription factors. Nucleic Acids Res (2006) 0.87
Linking the FMR1 alleles with small CGG expansions with neurodevelopmental disorders: preliminary data suggest an involvement of epigenetic mechanisms. Am J Med Genet A (2009) 0.86
Role of CTCF protein in regulating FMR1 locus transcription. PLoS Genet (2013) 0.85
Improved methodology for assessment of mRNA levels in blood of patients with FMR1 related disorders. BMC Clin Pathol (2009) 0.83
Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders. Front Genet (2014) 0.82
Identification of restriction endonucleases sensitive to 5-cytosine methylation at non-CpG sites, including expanded (CAG)n/(CTG)n repeats. Epigenetics (2011) 0.82
Bidirectional transcription of trinucleotide repeats: roles for excision repair. DNA Repair (Amst) (2013) 0.82
Chromatin changes in the development and pathology of the Fragile X-associated disorders and Friedreich ataxia. Biochim Biophys Acta (2012) 0.80
Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcription. Hum Mol Genet (2014) 0.79
Trinucleotide expansion in disease: why is there a length threshold? Curr Opin Genet Dev (2014) 0.79
Repeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders. Front Genet (2015) 0.77
The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med Genet (2012) 0.77
Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels. J Neurodev Disord (2013) 0.77
Human pluripotent stem cell models of Fragile X syndrome. Mol Cell Neurosci (2015) 0.77
Defining the role of the CGGBP1 protein in FMR1 gene expression. Eur J Hum Genet (2015) 0.76
Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers. Transfusion (2014) 0.76
Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells. Epigenetics Chromatin (2016) 0.76
Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome. Genes (Basel) (2016) 0.75
Study of the Genetic Etiology of Primary Ovarian Insufficiency: FMR1 Gene. Genes (Basel) (2016) 0.75
Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells. Stem Cells (2016) 0.75
Recent advances in assays for the fragile X-related disorders. Hum Genet (2017) 0.75
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science (1991) 7.16
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet (2000) 6.73
CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J (1998) 4.61
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet (1993) 4.57
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet (2001) 3.82
Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A (1994) 2.92
Translational suppression by trinucleotide repeat expansion at FMR1. Science (1995) 2.73
Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet (1999) 2.59
Methylation analysis of CGG sites in the CpG island of the human FMR1 gene. Hum Mol Genet (1992) 2.32
Creation of genomic methylation patterns. Nat Genet (1996) 2.15
Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet (2000) 1.85
Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet (1997) 1.74
Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum Mol Genet (1997) 1.70
Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A (1997) 1.70
High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet (1994) 1.68
Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet (1995) 1.63
Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet (1999) 1.53
A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum Mol Genet (1995) 1.50
A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. J Med Genet (2001) 1.44
In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet (1998) 1.34
Structural and functional characterization of the human FMR1 promoter reveals similarities with the hnRNP-A2 promoter region. Hum Mol Genet (1997) 1.20
Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental retardation syndrome. J Biol Chem (2000) 1.16
Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family. J Med Genet (1996) 1.10
In vitro DNA methylation inhibits FMR-1 promoter. Biochem Biophys Res Commun (1993) 1.05
Characterization of FMR1 promoter elements by in vivo-footprinting analysis. Am J Hum Genet (1997) 0.95
The human 20-kDa 5'-(CGG)(n)-3'-binding protein is targeted to the nucleus and affects the activity of the FMR1 promoter. J Biol Chem (2000) 0.95
Effect of in vitro promoter methylation and CGG repeat expansion on FMR-1 expression. Nucleic Acids Res (1997) 0.94
Instability of the CGG repeat and expression of the FMR1 protein in a male fragile X patient with a lung tumor. Am J Hum Genet (1995) 0.92
Methylation mosaicism of 5'-(CGG)(n)-3' repeats in fragile X, premutation and normal individuals. Nucleic Acids Res (2000) 0.91
Hypomethylation of an expanded FMR1 allele is not associated with a global DNA methylation defect. Am J Hum Genet (1999) 0.86
In vivo footprinting analysis of the FMR1 gene: proposals concerning gene regulation in high-functioning males. Am J Med Genet (1999) 0.82
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell (2003) 4.34
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet (2006) 3.69
Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nat Genet (2006) 3.54
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46
Heterozygous submicroscopic inversions involving olfactory receptor-gene clusters mediate the recurrent t(4;8)(p16;p23) translocation. Am J Hum Genet (2002) 3.09
The effect of genetic drift in a young genetically isolated population. Ann Hum Genet (2005) 2.75
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci (2007) 2.54
Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. Am J Hum Genet (2005) 2.40
De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet (2012) 2.34
Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet (2012) 2.34
Elements of morphology: standard terminology for the head and face. Am J Med Genet A (2009) 2.15
XLMR genes: update 2007. Eur J Hum Genet (2008) 2.07
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92
Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet (2003) 1.90
Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet (2004) 1.89
Linkage disequilibrium in young genetically isolated Dutch population. Eur J Hum Genet (2004) 1.80
Targeted high-throughput sequencing for diagnosis of genetically heterogeneous diseases: efficient mutation detection in Bardet-Biedl and Alström syndromes. J Med Genet (2012) 1.79
The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat (2006) 1.75
CFC syndrome. Am J Med Genet A (2003) 1.74
The ring 14 syndrome: clinical and molecular definition. Am J Med Genet A (2009) 1.70
The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med (2013) 1.70
Mapping the Wolf-Hirschhorn syndrome phenotype outside the currently accepted WHS critical region and defining a new critical region, WHSCR-2. Am J Hum Genet (2003) 1.67
Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet (2012) 1.61
Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat (2007) 1.56
Classification of familial amyotrophic lateral sclerosis by family history: effects on frequency of genes mutation. J Neurol Neurosurg Psychiatry (2012) 1.52
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A (2010) 1.50
Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet (2004) 1.46
Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol (2002) 1.42
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest (2012) 1.42
On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet (2008) 1.40
Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet (2005) 1.38
A case of 45,X male: genetic reevaluation and hormonal and metabolic follow-up in adult age. Fertil Steril (2008) 1.38
Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet (2012) 1.36
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
A genomic rearrangement resulting in a tandem duplication is associated with split hand-split foot malformation 3 (SHFM3) at 10q24. Hum Mol Genet (2003) 1.32
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Oral-facial-digital syndromes: review and diagnostic guidelines. Am J Med Genet A (2007) 1.29
Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. Nat Genet (2012) 1.25
Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol (2004) 1.22
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A (2007) 1.18
Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res (2009) 1.16
Evidence of inbreeding depression on human height. PLoS Genet (2012) 1.16
Genetic adaptation of fatty-acid metabolism: a human-specific haplotype increasing the biosynthesis of long-chain omega-3 and omega-6 fatty acids. Am J Hum Genet (2012) 1.13
Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the 5p15.2 region. Ann Rheum Dis (2012) 1.13
Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. Hum Mol Genet (2008) 1.13
Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet (2008) 1.12
A missense mutation in CASK causes FG syndrome in an Italian family. Am J Hum Genet (2009) 1.12
SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat (2011) 1.12
Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet (2005) 1.09
The Pitt-Hopkins syndrome: report of 16 new patients and clinical diagnostic criteria. Am J Med Genet A (2011) 1.08
Fragile X syndrome. Am J Med Genet C Semin Med Genet (2005) 1.07
Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients. BMC Med Genet (2006) 1.06
Room-temperature hydrogen sensing with heteronanostructures based on reduced graphene oxide and tin oxide. Angew Chem Int Ed Engl (2012) 1.04
The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. Cancer Biomark (2006) 1.04
The use of a non-lethal tool for evaluating toxicological hazard of organochlorine contaminants in Mediterranean cetaceans: new data 10 years after the first paper published in MPB. Mar Pollut Bull (2003) 1.02
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet (2010) 1.02
Electroclinical patterns and evolution of epilepsy in the 4p- syndrome. Epilepsia (2003) 1.01
Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet (2009) 1.01
The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med (2013) 0.99
Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients. Hum Mutat (2014) 0.99
A double cryptic chromosome imbalance is an important factor to explain phenotypic variability in Wolf-Hirschhorn syndrome. Eur J Hum Genet (2004) 0.99
PRRT2 phenotypes and penetrance of paroxysmal kinesigenic dyskinesia and infantile convulsions. Neurology (2012) 0.99
Expansion to full mutation of a FMR1 intermediate allele over two generations. Eur J Hum Genet (2004) 0.98
Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol (2004) 0.98
Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord (2003) 0.98
Nonaqueous synthesis of nanocrystalline semiconducting metal oxides for gas sensing. Angew Chem Int Ed Engl (2004) 0.98
A truncating mutation in the IL1RAPL1 gene is responsible for X-linked mental retardation in the MRX21 family. Am J Med Genet A (2006) 0.97
A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A (2008) 0.96
A case of Beckwith-Wiedemann syndrome caused by a cryptic 11p15 deletion encompassing the centromeric imprinted domain of the BWS locus. J Med Genet (2009) 0.95
Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology (Berl) (2014) 0.95
Hypo-phosphorylation of salivary peptidome as a clue to the molecular pathogenesis of autism spectrum disorders. J Proteome Res (2008) 0.95
Split-hand/split-foot malformation 3 (SHFM3) at 10q24, development of rapid diagnostic methods and gene expression from the region. Am J Med Genet A (2006) 0.95
The controlled deposition of metal oxides onto carbon nanotubes by atomic layer deposition: examples and a case study on the application of V2O4 coated nanotubes in gas sensing. Phys Chem Chem Phys (2009) 0.94
MID1 mutation screening in a large cohort of Opitz G/BBB syndrome patients: twenty-nine novel mutations identified. Hum Mutat (2007) 0.94
Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet (2008) 0.94
Array-based FMR1 sequencing and deletion analysis in patients with a fragile X syndrome-like phenotype. PLoS One (2010) 0.93
Association of adiposity genetic variants with menarche timing in 92,105 women of European descent. Am J Epidemiol (2013) 0.93
Identification of a candidate gene for astigmatism. Invest Ophthalmol Vis Sci (2013) 0.92
Exome sequencing and functional analyses suggest that SIX6 is a gene involved in an altered proliferation-differentiation balance early in life and optic nerve degeneration at old age. Hum Mol Genet (2013) 0.92
Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics (2008) 0.91
Quality of life in patients with schizophrenia--comparison of self-report and proxy assessments. Soc Psychiatry Psychiatr Epidemiol (2004) 0.91